DaVita Inc. (NYSE:DVA) Shares Sold by Doma Perpetual Capital Management LLC

Doma Perpetual Capital Management LLC lessened its stake in DaVita Inc. (NYSE:DVA) by 0.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 503,628 shares of the company’s stock after selling 1,853 shares during the quarter. DaVita comprises approximately 32.4% of Doma Perpetual Capital Management LLC’s holdings, making the stock its biggest holding. Doma Perpetual Capital Management LLC owned approximately 0.57% of DaVita worth $69,788,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Blue Trust Inc. increased its position in DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of DaVita in the fourth quarter worth $30,000. Family Firm Inc. purchased a new position in shares of DaVita in the 2nd quarter valued at $43,000. Versant Capital Management Inc lifted its holdings in shares of DaVita by 90.6% during the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after acquiring an additional 155 shares in the last quarter. Finally, Friedenthal Financial purchased a new stake in DaVita during the 2nd quarter worth $48,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Down 0.7 %

Shares of DaVita stock opened at $162.75 on Wednesday. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. The business has a 50-day moving average price of $151.04 and a 200 day moving average price of $142.52. DaVita Inc. has a fifty-two week low of $71.51 and a fifty-two week high of $166.04. The firm has a market cap of $13.65 billion, a P/E ratio of 18.49, a P/E/G ratio of 0.93 and a beta of 0.87.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The firm had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.15 billion. During the same period last year, the business posted $2.08 earnings per share. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, sell-side analysts forecast that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the company. TD Cowen boosted their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Bank of America upped their price target on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. UBS Group boosted their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. Finally, Truist Financial lifted their target price on DaVita from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $157.00.

Insider Transactions at DaVita

In related news, CEO Javier Rodriguez sold 32,176 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the completion of the transaction, the chief executive officer now owns 905,659 shares in the company, valued at approximately $141,219,407.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Joel Ackerman sold 64,029 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the sale, the chief financial officer now owns 111,481 shares of the company’s stock, valued at approximately $17,286,243.86. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Javier Rodriguez sold 32,176 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the transaction, the chief executive officer now directly owns 905,659 shares of the company’s stock, valued at $141,219,407.87. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 173,482 shares of company stock worth $27,387,069. 2.00% of the stock is currently owned by company insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.